Dementia with Lewy bodies (DLB) remains an area of high unmet need, with no approved disease-modifying therapies and significant clinical heterogeneity. At the recent AD/PD 2026 conference, new data from the Phase 2b RewinD-LB trial provided further insight into the potential of neflamapimod, a p38α MAP kinase inhibitor, to target key disease mechanisms.
In this Q&A by TouchNeurology, Prof. John-Paul Taylor (Professor of Translational Dementia Research, Northumberland, Tyne and Wear NHS Trust, UK) discusses the trial findings, their implications for understanding DLB biology and the rationale for ongoing Phase 3 development, as well as broader themes in neurodegenerative research, including precision medicine and mechanism-based therapeutic strategies:
https://touchneurology.com/insight/neflamapimod-as-a-potential-treatment-for-dementia-with-lewy-bodies-insights-from-the-rewind-lb-trial/
